SORT

1,2-Dioleoyl-sn-glycero-3-phosphate sodium salt (18:1 PA sodium salt) is an anionic lipid that can be used to prepare liposomes, micelles and artificial membranes.

DODAP is a cationic lipid utilized as the lipid component in liposomes (pKa = 5.59 in TNS binding tests). DODAP is employed for encapsulating siRNA and delivering immunostimulated chemotherapeutic agents both in vitro and in vivo. DODAP holds great promise for research in vaccines and inflammation.

5A2-SC8 is an ionizable amino lipid in lipid nanoparticles (LNPs) that shows high delivery potential and low in vivo toxicity, enabling efficient delivery of small RNAs such as siRNA and miRNA into tumor cells. 5A2-SC8 LNPs can confer a unique delivery fate of RNA within the liver, thereby changing the therapeutic outcomes in cancer models.

306Oi10 is a branched ionizable lipid that can be used to construct lipid nanoparticles (LNPs) for delivering messenger RNA. The surface ionization of lipid nanoparticles is related to the effectiveness of mRNA delivery. The tail of 306Oi10 has a one-carbon branch, which provides it with stronger surface ionization compared to lipids with linear tails, thereby enhancing its mRNA delivery efficacy. 306Oi10 can be used in research related to mRNA delivery.

306-O12B is an ionizable cationic lipid used to prepare lipid nanoparticles (LNPs) for the delivery of mRNA.

306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies.

PPZ-A10 is an ionizable cationic lipid. PPZ-A10 preferentially delivers mRNA to liver and spleen immune cells. Pi-LNPs containing PPZ-A10 can effectively deliver mRNA/siRNA to solid tumors.

NT1-O12B, an endogenous chemical and a neurotransmitter-derived lipidoid (NT-lipidoid), is an effective carrier for enhanced brain delivery of several blood-brain barrier (BBB)-impermeable cargos. Doping NT1-O12B into BBB-impermeable lipid nanoparticles (LNPs) gives the LNPs the ability to cross the BBB. NT-lipidoids formulation not only facilitate cargo crossing of the BBB, but also delivery of the cargo into neuronal cells for functional gene silencing or gene recombination.

113-O12B is a disulfide bond-containing ionizable cationic lipidoid. 113-O12B can be used in that generation of lipid nanoparticles (LNPs) for the delivery of mRNA.

244cis, a piperazine-containing ionizable cationic lipid, has been used to generate lipid nanoparticles (LNPs). LNPs containing 244cis and coated with mRNA reporter gene were specifically accumulated in mouse lungs compared with LNPs containing SM-102. Induces a decrease in serum chemokine (C-C motif) ligand 2 (CCL2) levels.

TT3 is an ionizable lipid-like material and a lipid nanoparticle (LLNs)-based mRNA delivery vector. TT3 exhibits liver and spleen specificity and excellent delivery efficiency.

93-O17S is an ionizable lipid. 93-O17S is involved in the construction of LNP. 93-O17S can achieve mRNA delivery to the spleen.

9A1P9 is a multi-tail ionizable cationic phospholipid. 9A1P9 induces membrane destabilization. 9A1P9 can be used for mRNA delivery t.

113-N16B is an ionizable cationic lipid that can be used for the synthesis of lipid nanoparticles. 113-N16B delivers mRNA to pulmonary endothelial cells. 113-N16B can be formulated as a component into hybrid lipid nanoparticles for lung-specific delivery of mRNA (including MFSD7C mRNA and luciferase mRNA) in mice. 113-N16B is applicable to research related to lymphangioleiomyomatosis, sickle cell disease, and hemolysis-induced lung injury.

RCB-02-4-8 is an ionizable cationic lipid that is used to form lipid nanoparticles (LNPs) to deliver mRNA. RCB-02-4-8 can improve the efficiency of lung transfection in mice.

Iso-A11B5C1 is an ionizable lipid that can be used in the synthesis of lipid nanoparticles (LNP). Iso-A11B5C1 is particularly suitable for muscle-specific mRNA delivery.

A28-C6B2 is an ionizable cationic lipid with a pK_a of 6.43, and can be used to generate lipid nanoparticles (LNPs) for mRNA delivery in vivo. A28-C6B2 can be studied in research for enhancing the selective delivery of mRNA to the spleen, particularly to antigen-presenting cells.

CP-LC-1422 is a homocysteine-derived ionizable amino lipid with high RNA delivery capability and can mediate high-level protein expression in vivo. CP-LC-1422 exhibits significant spleen targeting via intravenous injection in a lipid nanoparticle (LNP) formulation with no significant toxicity observed.

9C-SCC-10 is a crown-like biodegradable ionizable lipid. 9C-SCC-10 an be used to prepare lipid nanoparticles for delivering mRNA and targeting lung tissue. 9C-SCC-10 can be used for early detection and diagnosis of lung cancer.

Lipid C2 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNP) for mRNA delivery in vivo. LNPs containing Lipid C2 and encapsulating an mRNA reporter selectively accumulate in the liver and spleen but not the heart, lungs, or kidneys in mice. LNP containing Lipid C2 and encapsulating mRNA encoding the Epstein-Barr virus (EBV) protein latent membrane protein 2 (LMP-2), in combination with an anti-programmed cell death protein 1 (PD-1) antibody, decrease tumor volume and reverse T cell exhaustion, as well as increase the percentage of CD3⁺CD8⁺ central and CD3⁺CD8⁺ effector memory T cells and decrease the percentage of CD3⁺ T cells expressing Pd-1, in the spleen in a CT26 murine EBV-infected colon cancer model.